Skye Bioscience, Inc. Stock: price and management transactions · United States · SEC (Form 4)

About Skye Bioscience, Inc.

Skye Bioscience, Inc. is a U.S.-listed biopharmaceutical company trading on the NASDAQ under the ticker SKYE. The company is headquartered in San Diego, California, and was incorporated in Nevada on March 16, 2011. Today, Skye is positioned as a clinical-stage biotech focused on next-generation molecules that modulate G-protein-coupled receptors (GPCRs) to address obesity, overweight, and related metabolic conditions. For French-speaking investors in France, Belgium, and Switzerland, this places Skye in the high-risk, high-upside segment of small-cap biotech: it has no commercial revenue yet, but it is pursuing a differentiated scientific strategy in a very large therapeutic market. Skye’s strategic evolution is notable. The company previously communicated broader ambitions around cannabinoid-system biology, but its more recent messaging has shifted toward metabolic health and GPCR-based drug development. Its lead development asset is nimacimab, a clinical-stage candidate intended to explore new pathways in obesity and metabolic regulation. As a result, Skye remains firmly in the R&D phase: it is devoting substantially all of its efforts to pipeline advancement, preclinical and clinical work, manufacturing readiness, and capital raising. That is typical for a biotech at this stage, but it also means the company is highly dependent on external financing and on clinical execution. From a competitive standpoint, Skye operates in one of the most crowded areas of healthcare investing: obesity therapeutics. Large pharmaceutical companies and specialized biotech peers are all competing for share in a market driven by strong medical need and major commercial interest. Skye’s potential advantage lies in its scientific platform and in its focus on GPCR modulation, which may offer a distinct mechanism relative to more established treatment approaches. However, at this stage it remains a niche, pre-commercial player whose equity story depends largely on clinical data readouts, safety, efficacy signals, and future financing conditions. Geographically, the business is U.S.-centric, with its core operations in San Diego. For international investors, the key point is that SKYE is a Nasdaq-listed U.S. biotech, not a European healthcare company, and its operating, regulatory, and capital-markets exposure is therefore primarily American. Recent company highlights include its 2024 and 2025 financial and business updates, continued development work on nimacimab, and plans to broaden the pipeline through in-licensing or acquisitions of complementary metabolic health assets. A particularly important recent development came in March 2026, when Skye disclosed that it had received a Nasdaq deficiency notice because its share price had traded below the minimum $1.00 requirement for 30 consecutive business days. The notice does not immediately affect trading, but it is a material monitoring point for equity holders.